Liuniao Piaoling Pian (硫鸟嘌呤片)硫鸟嘌呤片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司
主要成分Active Ingredients
- 硫鸟嘌呤Liuniao Piaoling
药物知识说明
硫鸟嘌呤是一种在国家药监局注册认定的药品。标注生产企业为北京嘉林药业股份有限公司。
该药品暂无关联的活性成分信息。
该药品标注的生产企业为：北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司、北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司、北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 硫鸟嘌呤片) is a medicine registered with the national drug regulatory authority. It is manufactured by Chinese legal name: 北京嘉林药业股份有限公司.
No active ingredient relationships are currently recorded for this product in MedicineGraph.
Manufacturers recorded for this product: 北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司, 北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司, 北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 硫鸟嘌呤片Recorded Chinese name: 硫鸟嘌呤片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 25mg25 mg
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
生产企业Manufacturer
- 北京嘉林药业股份有限公司Chinese legal name: 北京嘉林药业股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20003840
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20003840
Manufacturer
Chinese legal name: 北京嘉林药业股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20003840
生产企业
北京嘉林药业股份有限公司(国产)
适应症
1、急性淋巴细胞白血病及急性非淋巴白血病的诱导缓解期及继续治疗期 2、慢性粒细胞白血病的慢性期及急变期
用法用量
成人常用量：口服，开始时每日2mg/kg或100mg/m2，一日一次或分次服用，如4周后临床未改进，白细胞未见抑制，可慎将每日剂量增至3mg/kg。维持量按每日2mg～3mg/kg或100mg/m2，一次或分次口服。联合化疗中75～200mg/m2，一次或分次服，连用5～7日。
不良反应
1、常见的毒性反应为骨髓抑制，可有白细胞和血小板减少； |2、消化系统反应：恶心、呕吐、食欲减退等胃肠道反应及肝功能损害，可伴有黄疸； |3、开始治疗的白血病及淋巴瘤患者可出现高尿酸血症，严重者可发生尿酸性肾病； |4、本品有抑制睾丸或卵巢功能的可能，引起闭经或精子缺乏，与药物的剂量和疗程有关，反应可能是不可逆的。
禁忌
已知对本品高度过敏的患者禁用。
贮藏
遮光，密封保存。
规格
25mg
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.